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ABSTRACT

The risk of infection associated with subcutaneous port (SQP) placement in patients with
neutropenia remains unclear. We reviewed the rate of early infectious complications (<30 days)
following SQP placement in pediatric oncology patients with /without neutropenia (absolute
neutrophil count (ANC)<500/mm3).

Baseline characteristics and infectious complications were compared between groups using
univariable and multivariable analysis.

A total of 614 SQP were placed in 542 patients. Compared to non-neutropenic patients, those
with neutropenia were more likely to have leukemia (94% vs 50%), pre-operative fever (22% vs
5%), pre-operative infection (19% vs 9%), and were younger (81 vs 109 months) (p values
<0.01).

After adjusting for fever and underlying-disease there was a non-significant association between
neutropenia and early post-operative infection (OR 2.42, 95% CI 0.82-7.18, p=0.116). Only preoperative fever was a predictor of infection (OR 6.09, 95% CI 2.08-17.81, p=0.564).

Neutropenia may not be a predictor of early postoperative infection following SQP placement.
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CHAPTER 1

INTRODUCTION

Tunneled central venous catheters are essential to the management of a variety of hematologic
and solid tumor malignancies.1 These devices allow long-term vascular access that permits the
administration of chemotherapy, frequent blood sampling, and the administration of antibiotics,
supportive medications, and total parenteral nutrition, thus making them indispensable.2 The
choice of which indwelling central venous catheter (double lumen tunneled catheters (DLTC),
single lumen tunneled catheters (SLTC), and subcutaneous ports (SQP)) is multifactorial.
Patient diagnosis will often dictate the choice of which tunneled device to use. Certain oncologic
diagnoses may require bone marrow transplantation and/or the need for multiple
chemotherapeutic agents that are not compatible with one another. This may necessitate a dual
lumen device and result in the patient receiving a DLTC.3

The size of the patient and lack of sufficient subcutaneous tissue may preclude the insertion of a
SQP. As a result, these patients (such as infants, for example) usually receive SLTC. Parent and
patient preference will often times guide which tunnelled device we use. The totally implantable
SQP offers the advantage of being completely covered, and when not in use, the patient may
shower, and swim, and engage in most regular activities. Often times, this device is chosen for
improved quality of life. A less desirable feature of this central line however, is that each time it
is accessed a needle must be inserted through the patient’s skin and subcutaneous tissue
overlying the port. This may cause pain, and unnecessary anxiety in some patients. Ultimately
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the repeated needle sticks may overshadow the potential benefit of a completely implantable
device. Finally, some centers use severe neutropenia (an absolute neutrophil count (ANC) of
less than 500 per mm3) as an exclusion criterion for insertion of SQP.3

Many pediatric oncology patients present with neutropenia at diagnosis, or experience this event
throughout their treatment with cytotoxic chemotherapy. Neutrophils are a type of white blood
cell responsible for identifying and eradicating foreign pathogens as well as killing microbes.4
The significance of neutropenia when selecting which tunneled central venous access port to use
is unclear and will be summarized in this literature review.

As with all invasive access devices, there is potential for complications. Early infection, those
occurring within 30 days of catheter insertion, is the most notable and frequent reported
complication to occur in 8-22% of cases.5-7 Subcutaneous ports are totally implantable
subcutaneous devices and are associated with the lowest rate of infectious complications among
central venous catheters.8 A prospective nonrandomized study performed by Ross and
colleagues examined complications in totally implantable vascular devices (SQP) and externally
exiting catheters (DLTC/SLTC). During the study interval 50 ports and 49 external catheters
were inserted. There were 15/41 (37%) complications in the external catheter group as
compared to 7/50 (14%) in the SQP group, p=0.02.9 Despite the trend towards less infectious
risk with totally implantable vascular devices, the consequence of infection may be more
significant. Catheter related infections, port site, or tunnel site infections, and surgical site
complications often necessitate removal of the SQP under general anaesthetic and delay in
therapy. Furthermore, implanted central venous catheter infections are associated with a
significant amount of morbidity and occasionally mortality.10,11 Siempos et al. conducted a
meta-analysis of comparative studies that reported on mortality of intensive care unit adult
2

patients with central line-associated bloodstream infection (CLABSI) and found that the
presence of CLABSI is associated with a higher mortality in critically ill adult patients after
matching for severity of illness (OR 1.70, 95% CI 1.00-2.90).

Efforts have thus been made to optimize timing for insertion of SQP to minimize the risk of early
postoperative infection. There is currently no standard protocol with regards to the placement of
SQP in the setting of neutropenia and therefore practices vary widely between centers. Insertion
may occur at the time of initial diagnosis, beginning of remission induction therapy, or following
resolution of neutropenia.2,3,12,13

Gutierrez et al. implemented an institutional protocol whereby children with neutropenia and
hematologic malignancies were excluded from placement of tunneled central venous catheters
until neutropenia resolved. Patients were bridged with a percutaneously inserted central catheter
(PICC) line in the interim. They conducted a retrospective study comparing the 100-day postinsertion outcomes with neutropenic patients prior to the implementation of the ANC exclusion
protocol and those after the implementation. They demonstrated that there was a strong trend
towards a lower incidence of removal for infection following initiation of the protocol, although
this was not statistically significant (4.1% [13/314] vs. 0.8% [1/126], p=0.07). The authors noted
that SQP were more likely than DLTC or SLTC to be removed within 100 days for all causes.
The logistic regression that was conducted identified neutropenia as the only independent risk
factor for early catheter removal. Interestingly, they also noted that the insertion of PICC lines
was not without some morbidity, with seven (15.6%) requiring removal due to infection (3),
deep venous thrombosis (2) and catheter fracture (2).12 However, this study was limited due to
only having assessed patients with hematologic malignancies, and including patients receiving
all forms of tunnelled central venous catheters.
3

Waiting for neutropenia to resolve prior to definitive line placement may result in a delay in
therapy and multiple unnecessary procedures. There is currently no consensus guiding
placement of SQP in pediatric oncology patients with neutropenia. The literature presents
conflicting opinions, with some studies documenting increased infectious risk,12,13,14-16 and others
demonstrating no significant increased risk.2,17,18

A retrospective review of 350 children with acute lymphoblastic leukemia, and aplastic anemia
found that patients with neutropenia (ANC<500/mm3) at the time of catheter placement had an
increased risk of catheter removal within 100 days of placement secondary to infection (12.4%
vs. 0.9%) compared to those without neutropenia.13 Additionally, in this same series, one patient
in the neutropenia group died of infectious related SQP complications compared to no patients in
the non-neutropenic group. They concluded that, when possible, central venous catheters,
particularly SQP, should be avoided in the presence of neutropenia. This retrospective review
only included children with a hematologic malignancy, and included all forms of tunnelled
central venous access.

Shaul et al. performed a retrospective review of all patients undergoing tunnelled central venous
catheter insertion at a single institution. They looked at those who developed fever and positive
blood culture drawn through the line within 45 days of insertion and compared them with control
patients (two controls per case). This study found that among the 473 lines that were placed,
early infections developed in 53 patients (12%). Neutropenia (defined in their study as ANC
<1000/mm3) was found in 16/53 infected patients compared with 8/106 controls (OR 5.30, 95%
CI 1.91-15.04, p=0.004). Interestingly, preoperative antibiotics were given to only 25/53
infected patients compared to 72/106 controls (p=0.02). They concluded that neutropenia and
failure to administer prophylactic antibiotics are risk factors for the development of early
4

tunneled catheter infections in pediatric patients.16 This study was limited in that the study
population was not confined to the pediatric oncology population. Further, the statistical
analysis showcased in the manuscript did not account for possible confounding variables.

Junqueira et al performed a retrospective study of children with leukemia undergoing SQP
insertion and found results contradictory to the previous authors. Early (<30 days) post
procedure complications were reviewed. They defined neutropenia as an ANC <500mm3. They
found that in 192 ports, the incidence of catheter associated infection did not differ between
neutropenic and non-neutropenic patients (15% vs. 24%, p=0.137).2 This study may be limited
by its low event rate, and failure to account for confounding in the statistical analysis.

Hoss et al. conducted a retrospective review of 183 pediatric oncology patients who underwent
SQP placement at a single centre. They compared patients with severe neutropenia
(ANC<500/mm3) to those with ANC>=500/mm3. The primary outcome of this study was the
presence of documented infection within the first 30 days post-procedure. They found that the
incidence of early infection was not significantly different between groups (12.5% neutropenia
vs. 4.5% non-neutropenia, p=0.08). They did find, however, that the rate of CLABSI per 1000
catheter days was higher for patients with severe neutropenia (p=0.045). Despite this, most
infections were able to be treated without SQP removal and the removal rate was not different
between groups (2.5% vs. 2.7 %, p=0.32).17 They concluded that port placement in patients with
severe neutropenia can be performed without an increased incidence of removal for infection.
This study was most limited by a small event rate (n=14).

5

The optimal timing of placement of a SQP in pediatric oncology patients, especially in the
setting of neutropenia, has been widely studied, and the findings in the literature vary. This may
be secondary to variation in the definition of severe neutropenia, or the patient population
studied (those with hematologic malignancies only vs. all pediatric oncology patients). Results
may differ as a result of small sample size and failure to consider confounding within the
analysis.

Therefore, the purpose of this study was to examine the association between neutropenia (i.e., the
exposure) and the development of early post-operative infectious complications) 30 days
following the initial procedure) (i.e., outcome) in pediatric oncology patients who underwent
SQP insertion.

Secondary objectives included documenting the incidence of early post-operative infectious
complications as well as to identify risk factors associated with SQP-related infectious
complications. Furthermore, we aim to describe the type of infectious complications that occur,
along with resulting intervention, if required, such as catheter removal, and antibiotics. We aim
to develop guidelines when considering optimal timing of SQP placement.

6

CHAPTER 2

METHODOLOGY

Patients

An Institutional Review Board-approved retrospective review was performed (Appendix).
Electronic medical records of all pediatric oncology patients undergoing SQP placement at St
Jude Children’s Research Hospital between January 2013 and December 2016 were reviewed.

Port placement

All procedures were performed under sterile technique in the operating room or in the
interventional radiology suite. Prophylactic antibiotics (intravenous cefuroxime (50mg/kg) or
clindamycin) were administered to all patients within 30 minutes of skin incision. All catheters
were inserted percutaneously under general anaesthesia. Ultrasound guidance was used to guide
internal jugular vein access, and anatomic landmarks were used to guide the subclavian
approach. The choice of vessel accessed was determined by the surgeon, or interventional
radiologist placing the line. Subcutaneous ports were either tunnelled and placed on the chest
wall, or placed in the sub clavicular position with minimal tunnel. Correct position was
confirmed using fluoroscopy during the procedure and a standard chest radiograph was obtained
immediately following port placement. The choice of diameter of catheter tubing was
determined by the weight of the patient, favoring 6.6 French catheters for patients < 30 kg.
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Post-operative subcutaneous port care and maintenance were performed according to the nursing
policy and procedure manual of this institution. While not in use, the subcutaneous port was
flushed with heparin (100 units/ml). While in use, the Huber needle of the port was changed
weekly under sterile technique. Sterile line dressings were applied as per hospital policy.

Data collection

Electronic medical records of all pediatric oncology patients undergoing subcutaneous port
placement were reviewed. We recorded age at insertion, body mass index (BMI), underlying
disease (i.e., leukemia, lymphoma, or solid tumor), history of previous central catheter
placement, documented preoperative infection (within two weeks of procedure), presence of
fever within 24 hours of port insertion, date of initiation of chemotherapy, location of port
placement, size of catheter tubing, and service placing subcutaneous port (interventional
radiology vs. general surgery). Most recent laboratory values were also collected prior to port
insertion and included: white blood cell count (WBC), platelet count, hemoglobin, glucose, and
absolute neutrophil count (ANC). Baseline characteristics and infectious complications were
compared between neutropenic and non-neutropenic patients.
In this study, the exposure of interest was neutropenia, which was defined as ANC<500/mm3.
ANC values were recorded as continuous measures but then categorized into a dichotomous
variable (<500/mm3 vs. >= 500/mm3) for data analysis.
The primary outcome was early infectious complications (i.e., within 30 days of SQP
placement). This was further defined as: 1) bacteremia (i.e, isolation of a pathogen from a blood
culture drawn through the lumen of the SQP 19-21); 2) surgical site infection (i.e.,
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presence of erythema, induration, and/or tenderness or evidence of purulent discharge at the
surgical incision); or 3) tract infection (i.e., presence of erythema, induration, and/or tenderness
within 2 cm of the port or catheter tubing.22,23

Statistical analysis

Descriptive statistics were calculated for patient characteristics with means and standard
deviations for continuous variables and frequency (percentage) for categorical variables. All
calculations were done using SAS software version 9.4.24 All tests were 2-sided and the
significance level was set at a p-value of less than 0.05. A t-test was performed to compare
continuous variables, and a Pearson chi-square test was performed to compare categorical
variables between patients with and without neutropenia.

Logistic Regression Analysis

The association between neutropenia and early post-operative infection rate was examined using
logistic regression analysis. We dichotomized ANC <500/mm3 (neutropenia) and >=500/mm3
(non-neutropenia). Clinical investigators pre-selected five potential confounding variables that
were assessed in this model: the presence of preoperative fever (within 24 hours of port
insertion), if the patient had received preoperative chemotherapy, history of previous central line,
underlying disease (leukemia, lymphoma, or solid tumor) and patient’s body mass index (BMI).
Underlying disease (hematologic malignancy vs. solid tumor) was pre-selected as the only
potential effect modifier.
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The presence of confounding effects was assessed by the change in estimate procedure and used
to determine the final model. Variables were entered into the model one at a time. If the
adjusted odds ratio changed by greater than ten percent, the variable was retained. Otherwise,
the variable was removed from the model. Effect modification was assessed by including a
multiplicative interaction term in the model.
To identify other potential risk factors for the development of early post-operative infectious
complications following SQP insertion, a univariable logistic regression analysis was performed.
Fourteen pre-selected variables of interest were examined: preoperative fever, underlying
disease, location of catheter (internal jugular vein vs. subclavian vein), location of port (chest
wall vs. sub clavicular), chemotherapy use prior to port insertion, service placing the SQP
(interventional radiology vs. surgery), history of previous central line, history of infection within
two weeks of SQP insertion, body mass index (BMI), age, gender, glucose, hemoglobin, catheter
size (diameter). All variables with a p-value <0.3 in the unnvariable analyses were entered into
the multivariable model and backwards selection was used to identify potential predictors of
infection. All variables with a p-value <0.25 were retained in the multivariable model. Odds
ratios and 95% confidence intervals were determined. All calculations were done using SAS
software version 9.4.24
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CHAPTER 3
RESULTS

Patients

In our study period, 614 subcutaneous ports were placed in 542 pediatric oncology patients. The
majority (79%) of ports were first-time insertions with the remainder being second (16%), third
(5%), or forth (1%) devices. Characteristics of the 614 ports are summarized in Table 1. There
were 272 (44%) ports were placed in children with solid tumors and 342 (56%) were placed in
children with a diagnosis of leukemia or lymphoma. The study cohort included 79 ports (13%)
placed in neutropenic patients and 535 (87%) placed in those who were non-neutropenic.
Statistically significant baseline differences between non-neutropenic and neutropenic patients
included age (mean age 109 vs 81 months), presence of fever within 24 hours of port placement
(5% vs 22%), underlying disease: leukemia (50% vs. 6%), and solid tumor (50 vs 96%),
respectively. The following variables were also found to be significantly different between the
two groups: chemotherapy prior to SQP insertion (35% vs. 23%), previous central line insertion
(40% vs. 20%), hemoglobin (10.9, 9.0 g/dL), and rate of infectious complications (2% vs. 9%),
respectively.

Infections

Characteristics of the 18 post-operative infections are summarized in Table 2. No patient in our
data set had more than one infection. Seven (9%) patients in the neutropenic group developed
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early post-operative infection compared to 11 patients (2%) in the non-neutropenic group. The
median time to infection was 14.5 days following subcutaneous port placement (range, 2 – 30
days). Most patients developed bacteremia (67%), with the remainder having port site infection
(22%) or the presence of both port site infection and positive blood culture (2%). The most
common organism isolated was Staphylococcus aureus (28%). The majority of patients (78%)
were neutropenic at the time of developing infectious complication. Treatment of infectious
complications included antibiotics only (56%), surgery only (i.e, removal
of subcutaneous port, 11%), and both surgery and antibiotics (33%). The majority of infectious
complications resulted in a delay of therapy (96%).

Regression Analysis

Baseline characteristics and infectious complications were compared between neutropenic and
non-neutropenic patients using multivariable logistic regression. No interaction was found
between neutropenia and underlying disease (p=0.97). The multivariable regression model did
find the presence of preoperative fever and disease (solid tumor vs. leukemia/lymphoma) to be
significant confounding variables (Table 3).
The model was therefore expressed as:

Y (log odds of having infection) = α +β1(NEUTROPENIA) + β2(DISEASE)+ β3(FEVER)
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After adjusting for underlying diagnosis (disease) and the presence of fever within 24 hours of
port placement, the increased risk of early post operative infection in the presence of neutropenia
was no longer significant (OR 2.42, 95% CI 0.82-7.18, p=0.1106).
Univariable logistic regression was used to identify potential risk factors for early post-operative
infection following SQP placement. These results are summarized in Table 5. Pre-operative
fever was found to be associated with increased risk of infection (OR 7.78, 95% CI 2.76-21.92).
A diagnosis of hematologic malignancy (leukemia/lymphoma) was similarly found to be
associated with increased risk of infection (OR 3.92, 95% CI 1.12-13.69, p=0.0321). The
initiating of chemotherapy prior to SQP placement was found to be associated with a lower risk
of post-operative infection (OR 0.42, 95% CI 0.12-1.48, p=0.1780). Finally, higher hemoglobin
levels were also found to be associated with decreased risk of infection with a 25% decrease in
risk for every on unit increase in hemoglobin. (OR 0.75, 95% CI 0.58-0.96, p=0.0251).
AfA second multivariable logistic model was constructed to examine the association between
these selected risk factors and early post operative infection followed by a Wald test for the
overall effects of ANC on infection. This model relied on backward elimination on all preselected risk factors. This process found two significant variables (fever and underlying
disease). A multivariable model was thus created adjusting for these two variables; the model
can be summarized in the equation bellow and the results are summarized in Table 6.

Y (log odds of having infection) = α +β1fever + β2underlying disease

The presence of fever within 24 hours of SQP placement was found significantly associated with
an increased risk of infection (OR 6.09, 95% CI 2.08-17.81, p<0.0010) after adjusting for
underlying disease (OR 4.67, 95% CI 2.08-17.81, p=0.0564).
13

CHAPTER 4

DISCUSSION

Overall five-year survival for pediatric malignancies has increased dramatically over the past 50
years. Cure rates for leukemia now approach 80% .25 This is largely secondary to improved
chemotherapeutic strategies as well as organizing multi-centered trials and standardized
treatment protocols. The use of tunneled central venous catheters is a mainstay of treatment of
most pediatric malignancies. It provides a safe route for delivery of these life-saving drugs, a
method of obtaining frequent blood tests, providing supplementary nutrition, as well as
supportive medication. Implanted central venous infections are associated with increased patient
morbidity and mortality13,26 and may also necessitate removal of the line. In an effort to
minimize the morbidity in this vulnerable population, the use of central lines in pediatric
oncology patients has been extensively studied. Unfortunately, the literature to date has
provided conflicting results. The objective of our study was to examine the relationship of
preoperative neutropenia on the early postoperative infection rate following subcutaneous port
placement. Secondly, we sought to identify other variables that may increase the likelihood of
infection following SQP placement.
The optimal timing of placement of tunneled central venous lines has been an area of interest in
several studies, specifically with regards to preoperative neutropenia. Neutrophils are cells
responsible for clearing the blood of foreign material (including microbes). It is well established
that the chance of infection is directly proportional to the severity and duration of neutropenia .27
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Historically, placement of SQP (and other invasive procedures) in the setting of severe
neutropenia has been discouraged due to the potential increased risk of serious infections and
wound healing.16 Some studies have demonstrated that neutropenia (ANC<=500-1000/mm3) at
the time of tunneled central venous line insertion has been associated with an increase in post
operative infection and line removal and therefore recommend delaying central line placement
until count recovery.28,29 Conversely, other studies have demonstrated that neutropenia is not a
significant risk factor for infection following central line placement.3,17 Neutropenia is a
common occurrence in the setting of cancer, both at the time of diagnosis and throughout
therapy. Some authors argue that although many oncology patients present with normal or
elevated neutrophil counts, these cells are likely immature and/or dysfunctional. Their ability to
fight infection therefore remains uncertain.30 The importance of neutropenia in the setting
vascular access remains controversial. In this study, we have demonstrated that, after adjusting
for pre-operative fever and underlying disease, while there appears to be an associated between
neutropenia and early post operative infection following SQP placement (OR 2.4, 95% CI 0.827.18), this association does not reach statistical significance (0.1106). This may be due to the
low event rate observed in this study (18/614). This finding is in keeping with several other
studies that examined early post-operative wound infections in the setting of neutropenia
following placement of tunneled lines.3,17
Other factors that have been studied with regards to infectious risk and central line placement
include site of line placement (internal jugular vein versus subclavian vein), type of catheter used
(subcutaneous port versus tunneled central access devices), age of patient, and the presence of
preoperative fever. We found that the choice of vessel (internal jugular vein versus subclavian
vein) did not influence infectious risk (OR 1.18, 95% CI 0.41-3.36, p=0.7570). This is in
15

keeping with the literature.31,32 Many studies have found that SQP are associated with the least
amount of infectious rate among central venous catheters.8 Our study only examined patient
following SQP placement and so we did not explore the effect of the type of device on risk of
infectious complications.
Historically, tunnelled central venous catheters were placed exclusively by the surgical
department. Over the past 15 years, however, there has been a shift in practice, wherein at many
centers these lines are now placed by the interventional radiology department. Some studies
have found that lines placed by the radiology department have been associated with decreased
cost and morbidity.33,34 Our study found that the service placing the SQP (interventional
radiology versus surgery) was not a risk factor for early infection (OR 1.23, 95% CI 0.40-3.79,
p=0.7185). This difference may be secondary to a more standardized approach to line care both
at the time of insertion (initial dressing) and post-operative management.
Several studies have found that the age of the patient at time of tunneled central venous line
placement may pre-dispose them to post-operative complications.17,35 These studies found an
increased risk of infectious complications following line placement in children less than 10 years
of age. Our study did not find age to be a predictive factor for early post-operative infection
following SQP placement (OR 1.00, 95% CI 1.00-1.00, p=0.3795).
Our study did find that for every unit increase in hemoglobin, the odds of developing a postoperative wound infection decreased by 0.75 (OR 0.75, 95% CI 0.58-0.96, p=0.0251). This is
not surprising, given the established literature demonstrating an association between anemia and
increased risks of postoperative complications (including infection). This may be secondary to
lower oxygen carrying capacity and the subsequent lower oxygen tension in tissues resulting in
poorer wound healing and in decreased local immunity.36,37
16

We also found, in the univariable regression, that patients with a diagnosis of leukemia or
lymphoma appeared to be almost four times more likely to develop an early post-operative
infectious complication as compared to patients diagnosed with a solid tumor (OR 3.92, 95% CI
1.12-13.69, p=0.0321). This relationship was maintained in the multivariable analysis though
become non statistically significant (OR 4.67, 95% CI 2.08-17.81, p=0.0564). This may be
understood by the fact that, in general, the hematologic malignancy population presents more
systemically unwell, and often with profound bone marrow suppression, as compared to the solid
tumor group. Further, both groups differ significantly with regards to timing of initiation of
chemotherapy as well as the types of chemotherapeutic agents used to treat the underlying
disease. Finally, the observed increase risk of infection associated with the leukemia/lymphoma
group may be exaggerated given our low event rate (only 3 infections occurred in solid tumor
patients with neutropenia), this is apparent by the wide confidence intervals observed.
The importance of pre-operative fever in the absence of an isolated pathogen and the risk of post
operative wound infection following line placement in the pediatric oncology patient remains
poorly defined. Fever is not uncommon in children with acute lymphoblastic and lymphocytic
leukemia. It is hypothesized to be secondary to the release of cytokines from leukemic cells, the
administration of certain drugs, or even the transfusion of blood products.38 While fever in an
oncology patient is often multifactorial, and may not be an indication of acute infection, it has
been found to be associated with a higher rate of post-operative infections following SQP
insertion.2 Similarly, our study demonstrated a significantly increased risk of infection following
SQP placement in patients that had a documented fever in the 24 hours preceding surgery (OR

17

6.09, CI 2.08-17.81, p=0.0010). This should be interpreted with some caution, given the wide
confidence intervals.
In our study period, the incidence of early post-operative infections following SQP placement
was 2.9% (18/614). This is comparable to the incidence of infections found in the literature (0.712.6%).11 Treatment of infectious complications required surgical removal of the SQP in just
under half of these patients (44%, 8/18). This is in contrast to the literature that has
demonstrated antibiotic treatment failure rate ranging from 11% 2 to 14%.11 This
difference may be secondary to the higher incidence of local (i.e., port site or surgical site)
infections noted in our group of patients (6/18). Almost all of our patients with infections,
salvaged with antibiotics or not, had a documented delay in therapy (17/18).

Limitations of our study

The main limitation of this study is the low event rate. Despite having 614 lines placed over
three years, we documented only 18 early post-operative infections. It is therefore difficult to
make any strong conclusions with regards to the association between neutropenia and infection.
While our multivariable regression model did not find a statistically significant association
between neutropenia and infectious complications, the odds ratio was still quite large (2.42). It
would be interesting to see how this relationship may change with a higher event rate. Our small
event rate also limited our ability to fit multiple variables into our second multivariable
regression model due to offer fitting and likely contributed to the wide confidence intervals seen
throughout our analyses.
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A second limitation of this study is that it is retrospective in nature and therefore has inherent
bias built into its design. An example of this was our definition of CLABSI. We chose to accept
all infections wherein a pathogen was isolated from a culture drawn through the central line.
However, a more restrictive measure would have involved comparing cultures between central
and peripheral venous samples and documenting a 5:1 ratio in microbe counts. This would have
eliminated the potential for contaminated specimens. Not all patient had peripheral and central
blood cultures drawn and therefore this comparison could not be made.

Conclusion and Future directions

The optimal timing of SQP placement in the pediatric oncology patient remains ill-defined. Our
results did not show a significant main effect of neutropenia on early post operative infection
following SQP placement. Univariable analysis found fever, underlying disease, previous
chemotherapy, and hemoglobin were significantly associated with infection, and when these
were assessed in the multivariable model, only fever was found to be associated with infection
after accounting for the other three variables. Further studies will be required to further assess
the relationship between neutropenia and fever on early post-operative wound infections
following central line placement in the pediatric oncology patients. Given the low event rate, a
multicenter prospective trial or large retrospective database would likely be necessary to further
evaluate this relationship.
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Table 1. Patient Characteristics by ANC level

Age

ANC >= 500/mm3
N = 535
109.3 (74.7)

ANC <500/mm3
N = 79
81.0 (58.7)

43% (202)
57% (265)

44% (33)
56% (42)

BMI

23.0 (70.0)

18.2 (5.5)

Fever
No
Yes
Chemo Prior
No
Yes

0.00021

F:M
1.51 (0.72,1.85)
0.12171
<0.00012

50% (268)
50% (267)

94% (74)
6% (5)

LL:ST
13.99 (5.57,35.16)
<0.00012

95% (510)
5% (25)

78% (62)
22% (17)

Y:N
5.59 (2.86,10.94)
0.03592

65% (348)
35% (187)

77% (61)
23% (218)

Y:N
0.55 (0.32,0.96)
0.00242

Previous Catheter
No
Yes

60% (323)
40% (212)

78% (62)
22% (17)

Y:N
0.42 (0.24,0.73)

Service Placing
IR
Surgery

26% (140)
72% (395)

24% (19)
76% (60)

Surgery:IR
1.12 (0.64,1.94)

Location Catheter
IJ
SCV

0.68852

0.14902
32% (172)
68% (363)

24% (19)
76% (60)

SCV:IJ
1.50 (0.87,2.58)
0.70612

Port site
Chest
Sub clavicular

50% (265)
50% (269)

52% (41)
48% (38)

Hemoglobin

10.97 (2.11)

9.00 (1.32)

Post Op Infection
No
Yes

P Value

0.9042

Gender
Female
Male

Disease
LL
ST

OR, 95% CI

CW:SCL
1.09 (0.68,1.76)
<0.00011
<0.00012

98% (510)
2% (11)

91% (72)
9% (7)

Y:N
0.22 (0.08,0.57)

Continuous variables presented as means and standard deviations. Numbers after percent are frequencies.
Tests used 1TTest; 2 Pearson X2 test. BMI (Body Mass Index). LL (Leukemia, Lymphoma). ST (Solid Tumor). IR
(Interventional Radiology). IJ (Internal Jugular Vein). SCV (Subclavian Vein). CW:SCL (Chest Wall, Subclavicular)
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Table 2. Early post operative infectious complications
Type of infection
Bacteremia
Port Site
Tunnel/track
Bacteremia and port

N
18
67% (12)
22% (4)
0% (0)
11% (2)

Organism Isolated
Capnocytopagea
Coag Neg Staph + Candida
Escherichia coli
Moraxella non-liquefaciens
Pseudomonas aeruginosa
Rothia mucilaginosa
Staphylococcus epidermidis
Staphyloccocus aureus
Streptococcus viridans

14

ANC at time of infection
0
100
300
400
500
600
900
2500

18

Intervention
Antibiotics
Surgical removal SQP
Antibiotics and surgery

18

Delay in therapy
Yes
No

18

7% (1)
7% (1)
21% (3)
7% (1)
7% (1)
7% (1)
7% (1)
28% (4)
7% (1)

56% (10)
11% 92)
6% 91)
6% 91)
6% (1)
6% (1)
6% (1)
6% (1)

56% (10)
11% (2)
33% (6)

94% (17)
6% (1)
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Table 3. Association between neutropenia and infection: Assessing confounding

OR

95% CI

P-value

Percent change

Neutropenia

4.63

1.74-12.33

0.0021

0.0000

BMI adjusted

4.68

1.75-12.48

0.0021

-1.07

Disease adjusted

3.32

1.19-9.27

0.0222

39.63

Previous Catheter
adjusted

4.44

1.64-12.00

0.0033

4.28

Fever adjusted

3.06

1.06-8.82

0.0386

1303.03

Chemo Prior adjusted

4.75

1.74-12.96

0.0023

-2.23
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Table 4. Association between neutropenia and infection adjusting for fever, and underlying
disease

OR

95% CI

P-value

Neutropenia
Y:N

2.42

0.82-7.18

0.1106

Fever
Y:N

4.72

1.55-14.37

0.0063

Disease
LL:ST

2.33

0.61-8.86

0.2158

LL (Leukemia, Lymphoma). ST (Solid Tumor). Y (Yes). N (No)
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Table 5. Univariable Analysis: Predictors of infection
OR

95% CI

P-value

Fever (Y:N)

7.78

2.76-21.93

0.0001

Disesae (LL:ST)

3.92

1.12-13.69

0.0321

Location Catheter
(SCV:IJ)

1.18

0.41-3.36

0.7570

Port Site
CW:SCL

1.45

0.54-3.85

0.4588

Chemo Prior
Y:N

0.42

0.12-1.48

0.1780

Service Placing
Sx:IR

1.23

0.40-3.79

0.7185

Previous Catheter
Y:N

0.64

0.22-1.82

0.4003

Preop Infection
Y:N

1.11

0.25-4.97

0.8849

BMI

1.00

1.00-1.00

0.6987

Age

1.00

1.00-1.00

0.3795

Gender
F:M

1.63

0.63-4.18

0.3124

Glucose

1.00

0.99-1.02

0.5379

Hemoglobin

0.75

0.58-0.96

0.0251

Catheter Size

1.08

0.79-1.50

0.6343

LL(Leukemia, Lymphoma). ST (Solid Tumor). IR (Interventional Radiology). IJ (Internal Jugular Vein). SCV
(Subclavian Vein). CW:SCL (Chest Wall, Subclavicular). Y (Yes). N (No)
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Table 6. Multivariable Analysis: Predictors of infection
OR
95% CI

P-value

Disease
LL:ST

4.67

2.08-17.81

0.0564

Fever
Y:N

6.09

2.08-17.81

0.0010

LL (Leukemia, Lymphoma). ST (Solid Tumor). Y (Yes). N (No).
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